Tags : Omniab


Genagon Signs a Worldwide License Agreement with Ligand for its

Shots: Ligand to receive upfront, milestones, and royalties for each of the product developed using OmniAb technology. Genagon to get WW rights for Ligand’s Omniab technology including the developed products OmniRat, OmniMouse, OmniFlic & OmniChicken and will fund the future development programs The focus of the agreement is to develop immune-oncology therapies based on Ligand’s […]Read More